The Impact of Course Title and Instructor Gender on Student Perceptions and Interest in a Women's and Gender Studies Course

Diversity awareness has enormous benefits, and universities in the United States increasingly require students to complete diversity-related courses. Prior research has demonstrated that students' initial attitudes toward these courses affect their subsequent engagement, as well as the quality of their learning experience; however, very little research has examined how these initial attitudes are formed. We conducted an experiment to examine this issue in the context of a women's and gender studies course in psychology. Participants read one of two identical course descriptions that varied only the course title (i.e., Psychology of Gender versus Psychology of Women) and instructor gender. Participants perceived a women-titled course to be narrowly focused compared to an identical gender-titled course and were more interested in taking the gender-titled course. Instructor gender had no effects on any of the variables. Additionally, female participants had more positive attitudes toward the course than male participants, regardless of title. Exploratory mediation analyses indicated that the main effects of course title and participant gender were mediated by perceptions of course content. Implications for improving student experiences and interest in diversity-related courses are discussed

Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial

Background Previous evidence indicates that adjuvant, short-course androgen deprivation therapy (ADT) improves metastasis-free survival when given with primary radiotherapy for intermediate-risk and high-risk localised prostate cancer. However, the value of ADT with postoperative radiotherapy after radical prostatectomy is unclear. Methods RADICALS-HD was an international randomised controlled trial to test the efficacy of ADT used in combination with postoperative radiotherapy for prostate cancer. Key eligibility criteria were indication for radiotherapy after radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to radiotherapy alone (no ADT) or radiotherapy with 6 months of ADT (short-course ADT), using monthly subcutaneous gonadotropin-releasing hormone analogue injections, daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as distant metastasis arising from prostate cancer or death from any cause. Standard survival analysis methods were used, accounting for randomisation stratification factors. The trial had 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 80% to 86% (hazard ratio [HR] 0·67). Analyses followed the intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov, NCT00541047. Findings Between Nov 22, 2007, and June 29, 2015, 1480 patients (median age 66 years [IQR 61–69]) were randomly assigned to receive no ADT (n=737) or short-course ADT (n=743) in addition to postoperative radiotherapy at 121 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 9·0 years (IQR 7·1–10·1), metastasis-free survival events were reported for 268 participants (142 in the no ADT group and 126 in the short-course ADT group; HR 0·886 [95% CI 0·688–1·140], p=0·35). 10-year metastasis-free survival was 79·2% (95% CI 75·4–82·5) in the no ADT group and 80·4% (76·6–83·6) in the short-course ADT group. Toxicity of grade 3 or higher was reported for 121 (17%) of 737 participants in the no ADT group and 100 (14%) of 743 in the short-course ADT group (p=0·15), with no treatment-related deaths. Interpretation Metastatic disease is uncommon following postoperative bed radiotherapy after radical prostatectomy. Adding 6 months of ADT to this radiotherapy did not improve metastasis-free survival compared with no ADT. These findings do not support the use of short-course ADT with postoperative radiotherapy in this patient population

Duration of androgen deprivation therapy with postoperative radiotherapy for prostate cancer: a comparison of long-course versus short-course androgen deprivation therapy in the RADICALS-HD randomised trial

Background Previous evidence supports androgen deprivation therapy (ADT) with primary radiotherapy as initial treatment for intermediate-risk and high-risk localised prostate cancer. However, the use and optimal duration of ADT with postoperative radiotherapy after radical prostatectomy remains uncertain. Methods RADICALS-HD was a randomised controlled trial of ADT duration within the RADICALS protocol. Here, we report on the comparison of short-course versus long-course ADT. Key eligibility criteria were indication for radiotherapy after previous radical prostatectomy for prostate cancer, prostate-specific antigen less than 5 ng/mL, absence of metastatic disease, and written consent. Participants were randomly assigned (1:1) to add 6 months of ADT (short-course ADT) or 24 months of ADT (long-course ADT) to radiotherapy, using subcutaneous gonadotrophin-releasing hormone analogue (monthly in the short-course ADT group and 3-monthly in the long-course ADT group), daily oral bicalutamide monotherapy 150 mg, or monthly subcutaneous degarelix. Randomisation was done centrally through minimisation with a random element, stratified by Gleason score, positive margins, radiotherapy timing, planned radiotherapy schedule, and planned type of ADT, in a computerised system. The allocated treatment was not masked. The primary outcome measure was metastasis-free survival, defined as metastasis arising from prostate cancer or death from any cause. The comparison had more than 80% power with two-sided α of 5% to detect an absolute increase in 10-year metastasis-free survival from 75% to 81% (hazard ratio [HR] 0·72). Standard time-to-event analyses were used. Analyses followed intention-to-treat principle. The trial is registered with the ISRCTN registry, ISRCTN40814031, and ClinicalTrials.gov , NCT00541047 . Findings Between Jan 30, 2008, and July 7, 2015, 1523 patients (median age 65 years, IQR 60–69) were randomly assigned to receive short-course ADT (n=761) or long-course ADT (n=762) in addition to postoperative radiotherapy at 138 centres in Canada, Denmark, Ireland, and the UK. With a median follow-up of 8·9 years (7·0–10·0), 313 metastasis-free survival events were reported overall (174 in the short-course ADT group and 139 in the long-course ADT group; HR 0·773 [95% CI 0·612–0·975]; p=0·029). 10-year metastasis-free survival was 71·9% (95% CI 67·6–75·7) in the short-course ADT group and 78·1% (74·2–81·5) in the long-course ADT group. Toxicity of grade 3 or higher was reported for 105 (14%) of 753 participants in the short-course ADT group and 142 (19%) of 757 participants in the long-course ADT group (p=0·025), with no treatment-related deaths. Interpretation Compared with adding 6 months of ADT, adding 24 months of ADT improved metastasis-free survival in people receiving postoperative radiotherapy. For individuals who can accept the additional duration of adverse effects, long-course ADT should be offered with postoperative radiotherapy. Funding Cancer Research UK, UK Research and Innovation (formerly Medical Research Council), and Canadian Cancer Society

Correlates and consequences of women and men\u27s group regulatory focus

According to regulatory focus theory (Higgins, 1997, 2001), individuals may take either a promotion or a prevention focus to obtain their goals. These two foci have consequences for emotional outcomes, behaviors, and decision-making biases. However, social groups also play a large role in people\u27s identity (Sedikides & Brewer, 2001; Tajfel & Turner, 1986). I examined the role of regulatory focus with respect to an important social identity, one\u27s gender group membership. In Studies 1 and 2, I examined the consequences of group promotion and prevention focus for individuals\u27 affective outcomes, using a measure of chronic focus (Study 1) and primed focus (Study 2). In Study 3, I examined some of the correlates of group regulatory focus in terms of beliefs about sexism and gender relations. In Study 4, I examined the extent to which group regulatory focus predicts decision-making biases in contexts relevant to the group. In Study 5, I examined the effects of group regulatory focus for impressions of promotion and prevention focused targets. The overall pattern of results from the first three studies suggests that group promotion and group prevention focus may have different antecedents and consequences for men and women. Women may be more comfortable adopting a group promotion focus, whereas men may be more comfortable adopting a group prevention focus. There was only limited support in Study 4 for the hypothesis that the effects of group regulatory focus would be limited to group contexts. In Study 5, ratings of an ingroup and outgroup target\u27s prototypicality were affected by the participants\u27 group regulatory focus, as well as the target\u27s regulatory focus and status as an ingroup or outgroup member. However, impressions were also strongly driven by the target\u27s regulatory focus: promotion focused targets were preferred over prevention focused targets. I discuss implications for regulatory focus theory in terms of understanding the differential consequences of regulatory focus for men and women, improved understanding of how promotion and prevention focus are perceived by observers, and direction for research on group regulatory focus

Naïve Theories About the Effects of Mood in Groups: A Preliminary Investigation

We examined the content and consequences of people's naïve theories about the effects of group mood. These theories are a potential input in Kelly and Spoor's (2006) Input-Process-Outcome model of group moods and performance. In Study 1, participants generated potential positive and negative consequences of group moods, which were coded using an adapted form of Bales' Interaction Process Analysis (Bales, 1970). Participants believed that positive and negative moods have implications for both task and relationship processes, and these consequences varied according to group type (creativity, friendship, decision making, and sport team). In Study 2, participants watched an ostensible group interaction among friends or strangers who had just had positive or negative experiences. Perceptions of the interaction varied in a manner consistent with naïve theories about group moods and their effects. Implications for future research on group moods are discussed

Overplaying the diversity card: when a superordinate group overrepresents the prevalence of a minority group

Despite the fact that groups and organizations often portray themselves as more diverse than they really are, the consequences of such practices for the minority who is overrepresented are not well understood. Focusing on Asian university students in Australia, we conducted three experiments to examine minority group members' perceptions when the superordinate group (the university) overrepresents the minority group in advertising. Minority group members tended to be less favorable toward overrepresentation compared to other types of representation (Studies 1 and 2), an effect that was most pronounced for those who strongly identified with their minority group (Study 3). The negative effect of minority overrepresentation was not detected among majority group members. If anything, in Study 1, majority group members were more positive toward overrepresentation and were more willing to help the superordinate group in an overrepresentation than a no minority representation condition. Future research directions and practical implications are discussed

The Evolutionary Significance of Affect in Groups: Communication and Group Bonding

Recent theorizing and research has attempted to explicate the functions of moods and emotions within small groups. In this paper, we examine these areas and suggest that affect in groups, as well as specific mechanisms to regulate and maintain certain affective states in groups, have had important roles in promoting group survival over evolutionary history. Specifically, we suggest that affect in groups serves a coordination function, which can take one of two forms. First, affect in groups quickly provides information about the environment and group structure to other group members, thus coordinating group activity via a communication function. Second, shared affect in groups coordinates group activity through fostering group bonds and group loyalty. These two functions of affect in groups are closely related and mutually reinforcing. Current research and directions for future research within an evolutionary perspective are also discussed

Impact of the COVID-19 pandemic on patients with hepatocellular carcinoma in the West of Scotland: a cohort study

Objective The COVID-19 pandemic had an undoubted impact on the provision of elective and emergency cancer care, including the diagnosis and management of patients with hepatocellular carcinoma (HCC). Our aim was to determine the effects of the COVID-19 pandemic on patients with HCC in the West of Scotland.Design This was a retrospective audit of a prospectively collated database of patients presented to the West of Scotland Multidisciplinary Team (MDT) between April and October 2020 (during the pandemic), comparing baseline demographics, characteristics of disease at presentation, diagnostic workup, treatment and outcomes with patients from April to October 2019 (pre pandemic).Results There was a 36.5% reduction in new cases referred to the MDT during the pandemic. Patients presented at a significantly later Barcelona Cancer Liver Clinic stage (24% stage D during the pandemic, 9.5% pre pandemic, p<0.001) and with a significantly higher Child-Pugh Score (46% Child-Pugh B/C during the pandemic vs 27% pre pandemic, p<0.001). We observed a reduction in overall survival (OS) among all patients with a median OS during the pandemic of 6 months versus 17 months pre pandemic (p=0.048).Conclusion The impact of the COVID-19 pandemic is likely to have contributed to a reduction in the presentation of new cases and survival among patients with HCC in the West of Scotland. The reason for this is likely multifactorial, but disruption of standard care is likely to have played a significant role. Resources should be provided to address the backlog and ensure there are robust investigation and management pathways going forward